Weâ€™re pleased to announce the results of Boston Childrenâ€™s Hospitalâ€™s 2012 CLARITY Challenge. The thoughtful submissions from 23 research teams, representing 10 countries, will inform the creation of much-needed â€śbest practicesâ€ť in genome analysis, interpretation and reportingâ€”providing the most meaningful results to patients and their families.
WINNER ($15,000 prize)
- Brigham and Women’s Hospital, Division of Genetics (Boston, Mass.), Massachusetts General Hospital (Boston, Mass.), Partners Laboratory for Molecular Medicine (Boston, Mass.), Brown University (Providence, RI), and Utrecht University (The Netherlands)
FINALISTS ($5,000 each)
- Genomatix (Munich, Germany), CeGaT (TĂĽbingen, Germany), Institute of Pathology, University Hospital of Bonn (Bonn, Germany)
- University of Iowa (Iowa City, Iowa)
- Clinical Institute of Medical Genetics (Ljubljana, Slovenia)
- Science for Life Laboratory (SciLifeLab), Karolinska Institute (Solna, Sweden)
- Scripps Genomic Medicine, Scripps Translational Science Institute (San Diego, Calif.)
- SimulConsult / Geisinger (Chestnut Hill, Mass. / Danville, Pa.)
- The Research Institute at Nationwide Children’s Hospital (Columbus, Ohio)
Learn about the CLARITY Challenge
Why the CLARITY Challenge?
The time is approaching when genomic information will inform everyday patient care. CLARITY is a collaborative effort to assure accurate, reliable interpretation of genomic data is communicated to patients and physicians. [Read More]
The application period for the CLARITY Challenge is now closed.
Boston Childrenâ€™s Hospital divided a prize of $25,000 between the winning team ($15,000) and two finalist teams ($5,000 each). Winners and finalists were selected by our panel of judges according to pre-specified criteria. The winner (Brigham and Women’s Hospital’s Division of Genetics, Massachusetts General Hospital, Partners Laboratory for Molecular Medicine, Brown University, and Utrecht University) and two finalists (the University of Iowa and Genomatix/CeGaT/Institute of Pathology, University Hospital of Bonn in Germany) were publicly announced in San Francisco on November 7, 2012 at the American Society of Human Genetics Conference.
Q: Is there a limit to the number of members per team?
A: There is no limit to the number of members per team.
Q: Are any of the judges bioinformaticians?
A: Yes. See below to learn more about the Challenge’s judges.
Q: Is there a Participation Agreement?
A: Yes. Please click here for a copy.
Q: What level of detail should be provided regarding methods?
A: Enough detail so that a qualified reader could understand and reproduce what was done. Similar to the standard expected of a peer reviewed publication.
Q: Will my teamâ€™s innovative methods be kept confidential?
A: Method innovations made by your team during participation in the Challenge are the team institutionâ€™s intellectual property and will be kept confidential by Boston Childrenâ€™s Hospital and the judges. Boston Childrenâ€™s Hospital does retain the right to publish the outcome of the Challenge, but will give the team and the institution time to review any publication in order to protect its intellectual property.Â Please review Article 4 of the Participation Agreement for additional information.
A diverse group of well-respected judges from the medical and technology communities will evaluate:
- The methods by which competitors analyze and interpret the genome sequences of the pediatric patients and their parents; and
- The ability of the competitors to synthesize the genomic data and produce clinically meaningful reports with actionable results for the participantsâ€™ physicians.
Elaine Lyon, PhD
Joseph Majzoub, MD
Boston Childrenâ€™s Hospital
Microsoft Health Solutions Group
David McCallie, Jr., MD
Cerner Medical Informatics Institute
Peter Szolovits, PhD
Massachusetts Institute of Technology
Huntington F. Willard, PhD